IP Library › Granted Patent US 9,273,136
Granted Patent B2
US 9,273,136 · App. 13/057,092 · Granted Mar 1, 2016

Fully human anti-human NKG2D monoclonal antibodies

Inventors: Christoph Rader (Olney, MD); Ka Yin Kwong (Gaithersburg, MD)
Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
C07K16/2851A61K2039/505C07K2317/21C07K2317/55C07K2317/56C07K2317/565C07K2317/73C07K2317/76C07K2317/92C07K2319/30C07K2319/32
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,273,136
App. No.
13/057,092
Granted
Mar 1, 2016
Kind
B2
Abstract

The invention relates to isolated fully human monoclonal antibodies having specificity for human NKG2D and compositions thereof. The invention further relates to methods for using such antibodies in treating diseases or conditions such as cancer, autoimmune disease, or infectious disease.

Claims (18)

1. An antibody having specificity for human NKG2D, comprising the following complementarity determining regions (CDRs): SEQ ID NO:11 (CDRH1), SEQ ID NO:12 (CDRH2), SEQ ID NO:13 (CDRH3), SEQ ID NO:14 (CDRL1), SEQ ID NO:15 (CDRL2), and SEQ ID NO:16 (CDRL3).

2. The antibody of claim 1 comprising:

(a) a heavy chain having at least 90% identity to the amino acid sequence of SEQ ID NO:9; and

(b) a light chain having at least 90% identity to the amino acid sequence of SEQ ID NO:10.

3. The antibody of claim 2 , wherein the heavy chain has at least 95% identity to the amino acid sequence of SEQ ID NO:9.

4. The antibody of claim 2 , wherein the heavy chain has the amino acid sequence of SEQ ID NO:9.

5. The antibody of claim 2 , wherein the light chain has at least 95% identity to the amino acid sequence of SEQ ID NO:10.

6. The antibody of claim 2 , wherein the light chain has the amino acid sequence of SEQ ID NO:10.

7. The antibody of claim 1 , wherein the antibody is selected from the group consisting of IgA1, IgA2, IgD, IgE, IgG1, IgG2, IgG3, IgG4, IgM, F(ab)2, Fv, scFv, IgGΔCH2, F(ab′)2, scFv2CH3, F(ab), VL, VH, scFv4, scFv3, scFv2, dsFv, Fv, scFv-Fc, (scFv)2, a non-depleting IgG, a diabody, and a bivalent antibody.

8. The antibody of claim 7 , wherein the antibody is an IgG selected from the group consisting of IgG1, IgG2, IgG3, IgG4, and synthetic IgG.

9. The antibody of claim 7 , wherein the antibody is a Fab.

10. The antibody of claim 7 , wherein the antibody has specificity for a tumor antigen.

11. The antibody of claim 7 , wherein the antibody is conjugated to a synthetic molecule.

12. The antibody of claim 11 , wherein the synthetic molecule is an antibody.

13. A composition comprising the antibody of claim 1 , and a pharmaceutically acceptable excipient.

14. A conjugate comprising the antibody of claim 1 .

15. The conjugate of claim 14 , further comprising (i) an agent for targeting a tumor antigen or an infectious disease antigen, (ii) a protein, or (iii) an antibody.

16. An antibody having specificity for human NKG2D comprising a light chain having the amino acid sequence of SEQ ID NO:10 and a heavy chain having the amino acid sequence of SEQ ID NO:9.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 28, 2011
From: RADER, CHRISTOPH; KWONG, KA YIN
To: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
Reel/Frame 026033/0159 →
Continuity (2)
Provisional Application 61086027 · Aug 4, 2008
Related Publication 20110150870A1 · Jun 23, 2011